The resulting information concerning potential benefits and risks of the new treatment is then considered in regulatory decision-making. Under normal circumstances, the strategies for the collection and processing of patient-reported outcome (PRO) and other clinical outcome assessment (COA) data in a clinical trial require thorough preparation, planning and implementation.